title: [Prevalence and prognostic significance of myeloid markers in adults with high-risk acute lymphoblastic leukemia].
abstract: OBJECTIVE
  The prognostic value of myeloid antigen expression in adult acute lymphoblastic leukemia (ALL) is controversial. The objective of this study was to evaluate the frequency and prognostic significance of myeloid antigen expression in adults with high risk ALL.
  
  
  METHODS
  Between June 1993 and July 2002, 222 adults patients with high-risk ALL were treated according to the PETHEMA LAL 93 protocol. The frequency of myeloid antigen expression, its association with other clinical and biologic variables and the prognostic significance in terms of complete remission (CR) rate, event free survival (EFS) and overall survival (OS) were analyzed.
  
  
  RESULTS
  Myeloid antigen expression was present in 96 out of 222 patients (43%). No association was observed between myeloid antigen expression and the main clinical and biologic characteristics of ALL. Response to treatment was slower in patients expressing myeloid antigens, but no differences were found in CR achievement, EFS or OS. The probability of EFS at 10 years for ALL patients without and with myeloid antigen expression was 35% and 34%, respectively, while the probability of OS at 10 years was 30% and 33%, respectively. This absence of differences in EFS and OS probabilities was also observed when only slow responding patients were analyzed.
  
  
  CONCLUSIONS
  In this study, myeloid antigen expression did not have prognostic influence in adult patients with high risk ALL.
authors.affiliation: Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain.
authors.forename: Esther
authors.initials: E
authors.lastname: Plensa
authors.forename: Josep Maria
authors.initials: JM
authors.lastname: Ribera
authors.forename: Albert
authors.initials: A
authors.lastname: Oriol
authors.forename: Concepción
authors.initials: C
authors.lastname: Bethencourt
authors.forename: Ricardo
authors.initials: R
authors.lastname: Parody
authors.forename: Jesús María
authors.initials: JM
authors.lastname: Hernández Ribas
authors.forename: María José
authors.initials: MJ
authors.lastname: Moreno
authors.forename: Eloy
authors.initials: E
authors.lastname: del Potro
authors.forename: Mar
authors.initials: M
authors.lastname: Tormo
authors.forename: Concepción
authors.initials: C
authors.lastname: Rivas
authors.forename: Joan
authors.initials: J
authors.lastname: Besalduch
authors.forename: Miguel Angel
authors.initials: MA
authors.lastname: Sanz
authors.forename: Jesús
authors.initials: J
authors.lastname: Arias
authors.forename: Javier
authors.initials: J
authors.lastname: Fernández Calvo
authors.forename: José María
authors.initials: JM
authors.lastname: Moraleda
authors.forename: Javier
authors.initials: J
authors.lastname: Bueno
authors.forename: Evarist
authors.initials: E
authors.lastname: Feliu
authors.forename: Juan José
authors.initials: JJ
authors.lastname: Ortega
mesh_terms: D000328:Adult; D015703:Antigens, CD / Q000097:blood*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000276:immunology* / Q000401:mortality*; D015995:Prevalence; D011379:Prognosis; D016019:Survival Analysis
chemical_list: D015703:Antigens, CD